Clinical trial
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
NCT00492531 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Terminated
Key facts
| NCT number | NCT00492531 |
|---|---|
| Title | Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease |
| Official title | Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease, Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Sildenafil, Placebo |
| Enrollment | 74 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jun 27, 2007 |
| Last update posted | Jan 6, 2016 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: